ArticleAAPS PharmSciTech2026
3D Printing of Hydrocortisone-loaded Eudragit RS Tablets: Influence of Plasticizers and Their Concentration on the Printability of Filaments.
Article in AAPS PharmSciTech, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although FDM is one of the prominent 3D printing technologies, and it has been widely investigated in pharmaceutical sciences, the printability of filaments remains a challenge. Therefore, our primary objective was to evaluate the effect of PEG 400, PEG 4000 and triethyl citrate at different concentrations (10%, 15% and 20% w/w) on the printability behavior of hydrocortisone-loaded Eudragit RS filaments. In this study, physical mixtures and their filaments were produced using a hot melt extruder and the properties of the filaments were examined by DSC, XRD, FESEM, FTIR, MFI and mechanical tests. Release behavior and hardness properties of the 3D-printed tablets were also evaluated. DSC and XRD results showed that the drug converted from crystalline to amorphous during hot melt extrusion and remained so during the 3D printing. FTIR results showed no chemical interactions between the drug and other excipients during hot melt extrusion and 3D printing. FESEM results of filaments showed that triethyl citrate-containing filaments had rougher surfaces, which makes them more suitable for 3D printing, while PEG-contained filaments had smoother surfaces. Mechanical tests showed that filaments containing triethyl citrate were stronger and tougher and had moderate ductility and stiffness. Overall, these filaments showed a good balance between these mechanical characteristics, which makes them a suitable candidate for 3D printing. Release studies showed that regardless of plasticizer type, the concentration of the plasticizer determines the extent of drug release. MFI test showed that formulations containing TEC presented a melt flow closer to 30 g/10 min compared to other formulations. Therefore, it can be deduced that TEC improves printability by enhancing melt flow better than the other two plasticizers (PEG 400 and PEG 4000). Based on the results, it can be concluded that triethyl citrate in 15% concentration is the best plasticizer for the production of hydrocortisone-loaded Eudragit RS tablets.
Indexed as
Identifiers
41588185What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.